Designer drugs 2015: assessment and management
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Recent designer drugs, also known as "legal highs," include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as "bath salts"); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has become popular among members of the military. Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908 · cited 1×
“Recovery from SUD in general is possible, and those who are treated have less disability than those who remain untreated [71].”
BackgroundDrug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622 · cited 1×
“and long-term treatment is likely necessary [70].”
Johnston, L., Miech, R., & O'Malley, P. (2020) · doi:10.3998/2027.42/162579 · Cited by 1,611
Cited by
New/emerging psychoactive substances and associated psychopathological consequences
Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. (2021) · Psychological Medicine · doi:10.1017/s0033291719001727 · Cited by 119
The clinical challenges of synthetic cathinones
Schifano, F., Napoletano, F., Arillotta, D., Zangani, C., Gilgar, L., Guirguis, A., Corkery, J. M., & Vento, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14132 · Cited by 73
Neurological aspects of drug misuse
Howard, R. S., Holmes, P., & Dargan, P. (2025) · Practical Neurology · doi:10.1136/pn-2023-003796 · Cited by 5
Metadata
- Authors
- Weaver, M. F., Hopper, J. A., & Gunderson, E. W.
- Venue
- Addiction Science & Clinical Practice
- Published
- 2015-03-25
- Volume
- 10
- Issue
- 1
- Pages
- 8-8
- ISSN
- 1940-0632 (ISSN-L)
- 1940-0640
- OpenAlex
- W2096428003
- Cited by
- 134
- References
- 3
- FWCI
- 37.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Designer drugs 2015: assessment and management. https://app.cochat.ai/papers/10.1186/s13722-015-0024-7
- The paper
- Weaver, M. F., Hopper, J. A., & Gunderson, E. W. (2015). Designer drugs 2015: assessment and management. Addiction Science & Clinical Practice. https://doi.org/10.1186/s13722-015-0024-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.